Translation Services for Biotech Companies

Biotech companies typically need translation across scientific manuscripts, posters, protocols, study reports, clinical documentation, informed consent forms, regulatory submissions, technical documentation, safety information, product claims, patent-related content, investor presentations, due diligence material, websites, press releases and partner communications. Many also need QMS documentation translation and SOP translation to support multilingual operations. AbroadLink provides biotech localization services through ISO-based workflows with qualified life sciences linguists, controlled terminology and risk-based workflow selection matched to department, content type, scientific context and target market.

Biotech localization services cover the translation and adaptation of biotech content for specific markets, languages and audiences. They typically include websites, product pages, investor materials, corporate communications, press releases, partner content and product development material, alongside regulated content such as clinical, regulatory and safety information. Localization preserves scientific accuracy and respects local market expectations. AbroadLink provides biotech localization services with life sciences linguists, controlled terminology, scientific and brand guidelines and risk-based workflow selection matched to content type, audience, scientific context and channel across biotech pipelines.

Biotech regulatory translation is the translation of content used during regulatory interactions for biotechnology products. It typically covers submissions, authority correspondence, RIM content, technical documentation, clinical documentation supporting submissions and authority-facing material. Terminology is regulatory-aware and aligned with prior submissions, harmonised wording and the procedural language expected by competent authorities. AbroadLink supports biotech regulatory translation through ISO-based workflows, qualified regulatory linguists and risk-based workflow selection. Regulatory strategy, scientific validity, authority interactions and submission decisions remain with the client's regulatory, scientific, clinical and legal teams.

General scientific translation covers a broad range of scientific content across disciplines. Biotechnology translation adds layers of modality-specific terminology, regulatory expectations, clinical evidence, patent-sensitive language and high-stakes external communication for early-stage and growing biotech organisations. It often involves coordinated translation across scientific publications, clinical documentation, regulatory submissions, IP content and corporate communications. AbroadLink supports both workflows but adjusts process, review depth, terminology setup and reviewer profile to match biotech subject matter, content risk and the cross-functional review needs of biotech organisations across pipelines and markets.

No. Lower-risk workflows do not lower the translation accuracy requirement. The objective remains accurate, complete and source-faithful translation for every biotech content type, including lower-risk internal drafts, administrative documents, repeated content, early-stage support material and non-critical marketing content. What changes between workflows is the depth of review, revision steps, terminology controls and validation activities applied to manage residual translation risk. A lower-risk workflow may be appropriate when content type, audience, scientific context, product development stage, regulatory context, target markets and your internal controls support that decision, not because accuracy expectations are reduced.

AbroadLink reviews content type, technology platform, scientific context, product development stage, audience, target markets and confidentiality before proposing a workflow. Regulatory submissions, clinical documentation, investigator materials, scientific manuscripts, technical documentation, safety information, patent-related content, product claims and investor presentations may justify ISO 17100 translation services with independent revision. Internal drafts, early-stage support content and lower-risk administrative documents may justify a lighter workflow. AbroadLink supports workflow selection, but scientific, clinical, regulatory, legal, IP and investor-relations strategy remain with your internal teams. See Linguistic Risk Assessment for more.

AI-assisted workflows can support biotechnology translation in controlled scenarios, typically as a pre-translation step followed by qualified human review and validation. AbroadLink offers controlled AI workflows through aiHubLink, using client terminology, prior translations and ISO-based processes. For regulatory submissions, clinical documentation, investigator materials, scientific manuscripts, technical documentation, safety information, patent-related content, product claims, investor presentations and authority-facing material, AI should only be used with clear governance, qualified review and traceability. AI does not replace life sciences linguists, independent revision or internal scientific, clinical, regulatory, legal and IP review steps.

No. Biotech localization services, biotechnology translation, biotech regulatory translation, multilingual biotech content support, scientific translations, ISO 17100 translation services, AI-assisted workflows, certificates and risk-based workflow support do not guarantee scientific acceptance, regulatory approval, authority acceptance, audit acceptance, clinical validation, patent protection, investor confidence, funding success, product approval, legal validity, market access or business outcomes. AbroadLink provides language services and translation workflow support. Decisions about scientific strategy, clinical strategy, regulatory strategy, IP strategy, legal review, investor communication and final content release remain with your scientific, clinical, regulatory, legal, IP and investor-relations stakeholders.